These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11996795)

  • 21. [Molecular cytogenetic study of bladder transitional cell carcinoma by FISH].
    Shou J; Wang M; Ma J
    Zhonghua Zhong Liu Za Zhi; 2000 Jan; 22(1):36-8. PubMed ID: 11776593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer?
    Pycha A; Mian C; Hofbauer J; Haitel A; Wiener H; Marberger M
    J Urol; 1998 Jan; 159(1):265-9. PubMed ID: 9400492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosomal aberrations in Bilharzial bladder cancer as detected by fluorescence in situ hybridization.
    Aly MS; Khaled HM
    Cancer Genet Cytogenet; 1999 Oct; 114(1):62-7. PubMed ID: 10526537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer.
    Simon R; Bürger H; Brinkschmidt C; Böcker W; Hertle L; Terpe HJ
    J Pathol; 1998 Aug; 185(4):345-51. PubMed ID: 9828832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].
    Zhang YG; Bi XG; Han YL; Cai Y; Xu X; Wu YP; Yang YL; Ma JH; Zhao P; Jia XM; Wang MR
    Ai Zheng; 2007 Feb; 26(2):189-93. PubMed ID: 17298751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma.
    Panani AD; Roussos C
    Anticancer Res; 2006; 26(1A):319-23. PubMed ID: 16475713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosomal aberrations in transitional cell carcinoma: its correlation with tumor behavior.
    Yu DS; Chen HI; Chang SY
    Urol Int; 2002; 69(2):129-35. PubMed ID: 12187044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer.
    Waldman FM; Carroll PR; Kerschmann R; Cohen MB; Field FG; Mayall BH
    Cancer Res; 1991 Jul; 51(14):3807-13. PubMed ID: 1676611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome.
    Cianciulli AM; Bovani R; Leonardo F; Antenucci A; Gandolfo GM; Giannarelli D; Leonardo C; Iori F; Laurenti C
    Int J Clin Lab Res; 2000; 30(1):5-11. PubMed ID: 10984125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of numerical chromosomal aberrations in bladder cancer detected by fluorescence in situ hybridization].
    Oka F
    Nihon Ika Daigaku Zasshi; 1995 Oct; 62(5):501-10. PubMed ID: 7499466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder.
    Watters AD; Ballantyne SA; Going JJ; Grigor KM; Bartlett JM
    BJU Int; 2000 Jan; 85(1):42-7. PubMed ID: 10619944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy.
    Bartlett JM; Adie L; Watters AD; Going JJ; Grigor KM
    BJU Int; 1999 Nov; 84(7):775-9. PubMed ID: 10532970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
    Bartlett JM; Watters AD; Ballantyne SA; Going JJ; Grigor KM; Cooke TG
    Br J Cancer; 1998 Jun; 77(12):2193-8. PubMed ID: 9649132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer.
    Inoue T; Nasu Y; Tsushima T; Miyaji Y; Murakami T; Kumon H
    Urol Res; 2000 Jan; 28(1):57-61. PubMed ID: 10732697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer.
    Watters AD; Latif Z; Forsyth A; Dunn I; Underwood MA; Grigor KM; Bartlett JM
    Br J Cancer; 2002 Sep; 87(6):654-8. PubMed ID: 12237776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH: prognostic implications.
    Cianciulli AM; Bovani R; Leonardo C; Iori F; Coletta AM; Marzano R; Antenucci A; Gandolfo GM; Laurenti C
    Eur J Histochem; 2001; 45(1):65-71. PubMed ID: 11411867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
    Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
    BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations.
    Zhang FF; Arber DA; Wilson TG; Kawachi MH; Slovak ML
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2317-28. PubMed ID: 9815630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer screening?
    Panani AD; Kozirakis D; Anastasiou J; Babanaraki A; Malovrouvas D; Roussos C
    Anticancer Res; 2006; 26(2A):1161-5. PubMed ID: 16619518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.